Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project

Hori, Megumi; Matsuda, Tomohiro; Shibata, Akiko; Katanoda, Kota; Sobue, Tomotaka; Nishimoto, Hiroshi

doi:10.1093/jjco/hyv088

Cited by 547 publications

(433 citation statements)

References 12 publications

Supporting

Mentioning

420

Contrasting

Order By: Relevance

“…Meanwhile, the average age of onset for ovarian cancer in the mutation-positive group, which is critical information for the appropriate age for RRSO, was approximately 7 years older than that of the mutationnegative group. However, this was still lower than that of the Japanese general population (61.1 years) [16,17]. The tendency of older age of onset for ovarian cancer in BRCA1/ 2 mutation carriers could not be confirmed statistically because the number of cases with ovarian cancer was too low.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

et al. 2017

View full text Add to dashboard Cite

The hereditary breast and ovarian cancer (HBOC) registration system of Japan was established by the Japanese HBOC Consortium. The first trial was registered in 2015 in four institutions to which some registration committee members belonged. We analyzed the information of 830 Japanese pedigrees, who underwent BRCA1/2 genetic testing, including mutation carriers with BRCA1 (N = 127) and BRCA2 (N = 115), and their families. The mutation-positive rate was 19.7%. Variants of uncertain significance were found in 6.5% of all individuals subjected to genetic testing for BRCA1/2. Compared to the United States, Japan had a higher mutation-positive rate in most categories, except for the groups with male breast cancer. Among the intrinsic subtypes of BRCA1-associated breast cancers, 75.8% were triple-negative. The incidence rate of contralateral breast cancer in BRCA1/2 mutation carriers was 0.99%/year. Among 240 mutation carriers, 26 and 62 patients underwent risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO), respectively; the respective frequencies of occult cancer were 7.1 and 3.2%. Metachronous breast cancer after RRM or peritoneal cancer after RRSO was not observed during the follow-up period. The nationwide registration system began last year and the system enables followup analysis in Japan.

show abstract

Section: Discussionmentioning

confidence: 88%

“…This is also~20 years younger than that in the Japanese general population (60.8 years) [16,17]. Meanwhile, the average age of onset for ovarian cancer in the mutation-positive group, which is critical information for the appropriate age for RRSO, was approximately 7 years older than that of the mutationnegative group.…”

Section: Discussionmentioning

confidence: 89%

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The age-standardized bladder cancer incidence rates (standard population: world population) for men and women were 8.6 and 1.8, respectively (standard population: in the Japanese 1985 model population, the incidence rate for men was 12.7, and that for women was 2.7). 30 Bladder cancer occurred 4.7-fold more frequently in men.…”

Section: Urinary Bladder Cancermentioning

confidence: 99%

Epidemiology of urothelial carcinoma

2017

View full text Add to dashboard Cite

The epithelium lining is defined as the mucosal surfaces of the renal collecting tubules, calyces and pelvis, as well as the ureter, bladder and urethra. The term "urothelium" is used to refer to these surfaces. Upper tract urothelial carcinoma is a rare subset of urothelial cancers with a poor prognosis. Urinary bladder cancer is the most common malignancy involving the urinary system. Upper tract urothelial carcinoma is more common in men than in women, with a male-to-female ratio of 2:1. The incidence of urinary bladder cancer is also higher in men. Cigarette smoking and occupational exposure are the main upper tract urothelial carcinoma and urinary bladder cancer risk factors, while other factors are more specific to the carcinogenesis of upper tract urothelial carcinoma (i.e. Balkan endemic nephropathy, Chinese herb nephropathy). In Egypt until recent years, urinary bladder cancer was the most frequently diagnosed cancer due to Schistosoma haematobium. Substantial knowledge exists regarding the causes of upper tract urothelial carcinoma and urinary bladder cancer, and epidemiological studies have identified various chemical carcinogens that are believed to be responsible for most cases of urothelial carcinoma. In the era of precision medicine, genetic effects might play a direct role in the initiation and progression of urothelial carcinoma.

show abstract

“…Its estimated incidence is 2-3 patients per 100 thousand people in Japan. Kidney dysfunction is a common complication, occurring in 18-56 % of multiple myeloma cases [10].…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange

et al. 2016

View full text Add to dashboard Cite

Myeloma cast nephropathy is a major complication of multiple myeloma. Recent evidence has demonstrated that the earlier induction of bortezomibbased chemotherapy with plasma exchange (PE) provides better results for kidney function and patient survival. Due to its non-selectivity, PE with albumin replacement carries the risk of fibrinogen loss, leading to bleeding. We herein report a case of successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy and selective PE. A 61-year-old woman who had a 20-year history of type II diabetes mellitus was admitted to our hospital for the evaluation of hypercalcemia, severe kidney dysfunction, and anemia. Subsequent bone marrow evaluation and renal biopsy revealed that she had multiple myeloma (IgG-j) and myeloma cast nephropathy. Ten days after admission, bortezomib-based chemotherapy with selective PE achieved rapid and thorough free light-chain (FLC) reduction; within a month, her kidney function had been recovered (creatinine level, 1.2 mg/dl). Her serum fibrinogen level was not reduced, and no bleeding complication occurred. Five months later, autologous hematopoietic stem-cell transplantation was performed successfully, and the patient's kidney function was stable (creatinine level, 1.1 mg/dl) thereafter. This case report demonstrates the importance of early induction therapy with bortezomib-based chemotherapy and PE in a patient with myeloma cast nephropathy, which is especially applicable in patients aged \65 years. In addition, it shows that selective PE is a safe and effective method of FLC removal.

show abstract

Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project

Cited by 547 publications

References 12 publications

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

Epidemiology of urothelial carcinoma

Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange

Contact Info

Product

Resources

About